Skip to main content
OpenTrials

Clinical trial condition

Mycosis Fungoides

Explore clinical trials studying Mycosis Fungoides. Study availability and eligibility vary by location and protocol.

307 public trials 30 recruiting studies
Refine in advanced search Browse all conditions

Mycosis Fungoides trial results

Completed

Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)

NCT01007448

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Florida Academic Dermatology Centers Miami, Florida, United States
  • Emory University Atlanta, Georgia, United States
  • Rush University Chicago, Illinois, United States
View all 17 locations
View Trial Details
Completed

Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome

NCT02243579

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +19 more
Locations
  • Stanford Cancer Institute Palo Alto Palo Alto, California, United States
  • Yale University New Haven, Connecticut, United States
  • Moffitt Cancer Center Tampa, Florida, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
View Trial Details
Completed

Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

NCT00005799

Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adenocarcinoma, Adult Acute Lymphoblastic Leukemia in Remission, +105 more
Locations
  • City of Hope Medical Center Duarte, California, United States
  • Stanford University Hospitals and Clinics Stanford, California, United States
  • University of Colorado Denver, Colorado, United States
  • Baylor University Medical Center Dallas, Texas, United States
View Trial Details
Completed

Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma

NCT00438802

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoblastic Lymphadenopathy, +14 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Holden Comprehensive Cancer Center at University of Iowa Iowa City, Iowa, United States
  • Mayo Clinic Cancer Center Rochester, Minnesota, United States
View Trial Details

Related conditions